Barabas Arpad Z, Cole Chad D, Graeff Richard M, Kovacs Zoltan B, Lafreniere Rene
Department of Surgery, University of Calgary, Calgary, AB, Canada.
Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA.
Hum Antibodies. 2016;24(3-4):53-57. doi: 10.3233/HAB-160295.
Employing passive immunization - using a heterologous anti-CD38 IgG antibody containing serum - in SCID mice injected subcutaneously with human multiple myeloma cells, we have shown that treatments with the antiserum - especially in the presence of complement - significantly decreased cancer growth. However, administered antibody and complement was not sufficient in amount to prevent cancer cell multiplication and cancer growth expansion to a satisfactory degree. Larger volumes of the same components more than likely would have further reduced cancer growth and prolonged the life of mice. In control mice, cancer growth progressed faster proving that lytic immune response against multiple myeloma cells is necessary for cancer cell kill.
